Equities research analysts predict that Esperion Therapeutics Inc (NASDAQ:ESPR) will report sales of $930,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Esperion Therapeutics’ earnings. The highest sales estimate is $1.00 million and the lowest is $900,000.00. The firm is scheduled to announce its next earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Esperion Therapeutics will report full-year sales of $148.13 million for the current year, with estimates ranging from $145.42 million to $150.00 million. For the next year, analysts anticipate that the business will report sales of $160.36 million, with estimates ranging from $7.10 million to $207.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $2.43. The company had revenue of $145.42 million during the quarter, compared to analysts’ expectations of $69.35 million. During the same quarter last year, the firm posted ($1.73) earnings per share.
In other Esperion Therapeutics news, CEO Timothy M. Mayleben bought 5,000 shares of Esperion Therapeutics stock in a transaction that occurred on Friday, June 28th. The stock was acquired at an average cost of $46.00 per share, for a total transaction of $230,000.00. Following the completion of the transaction, the chief executive officer now directly owns 66,163 shares in the company, valued at $3,043,498. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.70% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. grew its position in Esperion Therapeutics by 44.4% during the fourth quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 291 shares in the last quarter. Parallel Advisors LLC purchased a new position in Esperion Therapeutics during the first quarter worth about $80,000. Rehmann Capital Advisory Group purchased a new position in Esperion Therapeutics during the fourth quarter worth about $97,000. Marshall Wace North America L.P. purchased a new position in Esperion Therapeutics during the first quarter worth about $164,000. Finally, Marshall Wace LLP purchased a new position in Esperion Therapeutics during the first quarter worth about $186,000.
Shares of NASDAQ ESPR traded down $1.24 during mid-day trading on Friday, hitting $45.51. The company had a trading volume of 584,200 shares, compared to its average volume of 564,038. The firm has a market capitalization of $1.26 billion, a P/E ratio of -6.04 and a beta of 1.72. Esperion Therapeutics has a 1 year low of $36.06 and a 1 year high of $60.99. The business’s 50-day simple moving average is $48.98.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
See Also: Market Perform
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.